NO20010284L - Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) - Google Patents
Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)Info
- Publication number
- NO20010284L NO20010284L NO20010284A NO20010284A NO20010284L NO 20010284 L NO20010284 L NO 20010284L NO 20010284 A NO20010284 A NO 20010284A NO 20010284 A NO20010284 A NO 20010284A NO 20010284 L NO20010284 L NO 20010284L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- pacap
- adenylate cyclase
- activating polypeptide
- pituitary adenylate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
Abstract
Det beskrives nye analoger av PACAP (hypofyse adenylat cyclase aktiverende polypeptid) som er agonister av PACAP-reseptorene og som sådanne er anvendelige for behandling av cerebrovaskulær ischemi, hannkjønn impotens, motor neuronsykdom, nevropati, smerte, depresjon, angstlidelser, hjernetraume, hukommelsessvikt, demens, kognitiv lidelse, sentralnervesystem sykdommer (så som Parkinson's sykdom, Alzheimer's sykdom), migrene, neurodegenerative sykdommer, ischemisk hjertesykdom, myokardialt infarkt, fibrose, restenose, diabetes mellitus, muskelsykdom, gastrisk ulcer, slag, aterosklerose, hypertensjon, septisk sjokk, trombose, retina-sykdom, kardiovaskulær sykdom, nyresvikt og hjertesvikt og forhindring av neuronal celledød hos et pattedyr. Det beskrives også farmasøytiske preparater anvendelige derfor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11954098A | 1998-07-20 | 1998-07-20 | |
PCT/EP1999/003020 WO2000005260A1 (en) | 1998-07-20 | 1999-04-30 | Peptide analogues of pacap |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20010284D0 NO20010284D0 (no) | 2001-01-17 |
NO20010284L true NO20010284L (no) | 2001-03-19 |
Family
ID=22384966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20010284A NO20010284L (no) | 1998-07-20 | 2001-01-17 | Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP1098906B1 (no) |
JP (2) | JP2002521390A (no) |
AR (1) | AR019131A1 (no) |
AT (1) | ATE449789T1 (no) |
AU (1) | AU3826899A (no) |
CA (1) | CA2335341A1 (no) |
CZ (1) | CZ2001253A3 (no) |
DE (1) | DE69941708D1 (no) |
DK (1) | DK1098906T3 (no) |
ES (1) | ES2335827T3 (no) |
HU (1) | HUP0104934A3 (no) |
NO (1) | NO20010284L (no) |
PL (1) | PL345583A1 (no) |
TW (1) | TWI221845B (no) |
WO (1) | WO2000005260A1 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6972319B1 (en) | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
SK5552002A3 (en) * | 1999-09-28 | 2003-05-02 | Bayer Ag | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
JP2004500906A (ja) | 1999-11-12 | 2004-01-15 | ルーベン, レオ | 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド |
EP1257575B1 (en) * | 2000-02-18 | 2007-02-28 | Dabur Research Foundation | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
EP1257576B1 (en) | 2000-02-18 | 2004-09-15 | Dabur Research Foundation | Vasoactive intestinal peptide analogs |
CA2428552A1 (en) * | 2000-11-28 | 2002-06-06 | Mondobiotech Sa | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
JP2002293799A (ja) * | 2001-03-29 | 2002-10-09 | Itoham Foods Inc | 新規ペプチド及びそれを含有する消化管運動抑制剤 |
AR036400A1 (es) | 2001-08-30 | 2004-09-08 | Stem Cell Therapeutics Inc | Regulacion combinada de la produccion de celulas nerviosas. |
WO2003024472A2 (en) * | 2001-09-14 | 2003-03-27 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof |
AU2003228050A1 (en) * | 2002-05-03 | 2003-11-17 | Neuronova Ab | Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders |
DE60326723D1 (de) * | 2002-06-10 | 2009-04-30 | Mondobiotech Licensing Out Ag | Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose |
CA2492442A1 (en) | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
EP1583550A2 (en) | 2003-01-16 | 2005-10-12 | D. Collen Research Foundation vzw | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
AU2005211847B2 (en) | 2004-02-13 | 2011-02-24 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis |
US7595294B2 (en) * | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
JP2006306770A (ja) * | 2005-04-27 | 2006-11-09 | Nidek Co Ltd | 眼疾患治療剤 |
KR20080074108A (ko) | 2005-09-27 | 2008-08-12 | 스템 셀 테라퓨틱스 코포레이션 | 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식 |
WO2007050651A1 (en) | 2005-10-26 | 2007-05-03 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
AU2010313122A1 (en) * | 2009-11-02 | 2012-05-24 | The Administrators Of The Tulane Educational Fund | Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
SG11201506407VA (en) * | 2013-02-15 | 2015-09-29 | Univ Jefferson | Kit for tumor imaging |
EP3683237A1 (en) | 2013-03-15 | 2020-07-22 | Amgen Inc. | Human pac1 antibodies |
EP3019184A4 (en) * | 2013-06-07 | 2017-04-05 | The Administrators of the Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
WO2015023890A1 (en) * | 2013-08-14 | 2015-02-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
CA2930330A1 (en) * | 2013-12-27 | 2015-07-02 | Dignity Health | Diagnosing and treating alzheimer's disease |
MX2017003247A (es) | 2014-09-15 | 2017-11-30 | Amgen Inc | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. |
US10822408B2 (en) | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
CN109563144B (zh) | 2016-06-01 | 2023-03-28 | 雅斯娜 | 化合物 |
CA3049212A1 (en) | 2017-01-05 | 2018-07-12 | The Regents Of The University Of California | Pac1 receptor agonists (maxcaps) and uses thereof |
JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Pac1抗体及びその使用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS277405B6 (en) * | 1986-06-12 | 1993-03-17 | Vyzk Ustav Farm Biochem Sp | Peptides with 1-amino-1-cycloalkane carboxylic acid |
US5128242A (en) * | 1989-06-19 | 1992-07-07 | The Administrators Of The Tulane Educational Fund | Hypothalamic polypeptides with adenylate cyclase stimulating activity |
US5623050A (en) * | 1991-08-22 | 1997-04-22 | Takeda Chemical Industries, Ltd. | Stable polypeptides having c-AMP production enhancing activity and the use thereof |
JP3354173B2 (ja) * | 1991-08-22 | 2002-12-09 | 武田薬品工業株式会社 | ポリペプチドおよびその用途 |
WO1996009318A1 (en) * | 1994-09-22 | 1996-03-28 | The Administrators Of The Tulane Educational Fund | Method and pharmaceutical composition for prevention and treatment of brain damage |
EP0820296A4 (en) * | 1995-04-14 | 1999-06-30 | Univ Tulane | ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR |
US5753206A (en) * | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
AU682638B2 (en) * | 1995-06-09 | 1997-10-09 | ILS, Inc. | Peptide, bronchodilator and blood flow ameliorant |
US5723577A (en) * | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
US5955574A (en) * | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
WO1997007452A1 (en) * | 1995-08-15 | 1997-02-27 | International Software Machines | Programmable compiler |
-
1999
- 1999-04-30 WO PCT/EP1999/003020 patent/WO2000005260A1/en active Application Filing
- 1999-04-30 AT AT99920844T patent/ATE449789T1/de not_active IP Right Cessation
- 1999-04-30 DK DK99920844.0T patent/DK1098906T3/da active
- 1999-04-30 CA CA002335341A patent/CA2335341A1/en not_active Abandoned
- 1999-04-30 JP JP2000561216A patent/JP2002521390A/ja not_active Ceased
- 1999-04-30 AU AU38268/99A patent/AU3826899A/en not_active Abandoned
- 1999-04-30 CZ CZ2001253A patent/CZ2001253A3/cs unknown
- 1999-04-30 HU HU0104934A patent/HUP0104934A3/hu unknown
- 1999-04-30 ES ES99920844T patent/ES2335827T3/es not_active Expired - Lifetime
- 1999-04-30 PL PL99345583A patent/PL345583A1/xx not_active Application Discontinuation
- 1999-04-30 DE DE69941708T patent/DE69941708D1/de not_active Expired - Lifetime
- 1999-04-30 EP EP99920844A patent/EP1098906B1/en not_active Expired - Lifetime
- 1999-04-30 EP EP09174102A patent/EP2161282A1/en not_active Withdrawn
- 1999-05-03 AR ARP990102060A patent/AR019131A1/es not_active Application Discontinuation
- 1999-05-29 TW TW088108929A patent/TWI221845B/zh not_active IP Right Cessation
-
2001
- 2001-01-17 NO NO20010284A patent/NO20010284L/no not_active Application Discontinuation
-
2010
- 2010-03-23 JP JP2010066707A patent/JP2010189398A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
ATE449789T1 (de) | 2009-12-15 |
WO2000005260A1 (en) | 2000-02-03 |
ES2335827T3 (es) | 2010-04-05 |
AU3826899A (en) | 2000-02-14 |
PL345583A1 (en) | 2001-12-17 |
CZ2001253A3 (cs) | 2001-11-14 |
HUP0104934A3 (en) | 2002-05-28 |
AR019131A1 (es) | 2001-12-26 |
DK1098906T3 (da) | 2010-03-29 |
EP2161282A1 (en) | 2010-03-10 |
EP1098906A1 (en) | 2001-05-16 |
CA2335341A1 (en) | 2000-02-03 |
JP2002521390A (ja) | 2002-07-16 |
NO20010284D0 (no) | 2001-01-17 |
HUP0104934A2 (hu) | 2002-04-29 |
JP2010189398A (ja) | 2010-09-02 |
TWI221845B (en) | 2004-10-11 |
EP1098906B1 (en) | 2009-11-25 |
DE69941708D1 (de) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20010284L (no) | Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) | |
Hirose et al. | N-acyl 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist | |
Jensen et al. | Interaction of CCK with pancreatic acinar cells | |
Cabrele et al. | Molecular characterization of the ligand–receptor interaction of the neuropeptide Y family | |
US8729227B2 (en) | Compounds for control of appetite | |
CA2162924A1 (en) | New peptide antagonists at glutamate and nmda receptors | |
NZ250878A (en) | Substituted sulphamoyl derivatives and medicaments | |
Kaga et al. | Emerging functions of neuropeptide Y Y2 receptors in the brain | |
CA2318800A1 (en) | Fluorine-containing amino acid derivatives | |
JPH10504569A (ja) | 向代謝性グルタメート受容体拮抗剤としてのピロリジニルジカルボン酸誘導体 | |
CZ287948B6 (cs) | Peptidový derivát uvolňující růstový hormon, farmaceutický prostředek s jeho obsahem a jejich použití | |
JPS63258894A (ja) | アミノ酸誘導体 | |
EP1116727A4 (en) | PEPTIDE DERIVATIVE | |
Oka et al. | Endogenous GLP-1 is involved in β-amyloid protein-induced memory impairment and hippocampal neuronal death in rats | |
Mashal et al. | The effects of cholecystokinin on dopaminergic mechanisms in rat striatum | |
NZ332829A (en) | Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases | |
DE602004010529T2 (de) | 2-amino-5-benzoylthiazol npy-antagonisten | |
Meena et al. | Synthesis of CNS active thyrotropin-releasing hormone (TRH)-like peptides: Biological evaluation and effect on cognitive impairment induced by cerebral ischemia in mice | |
US6417159B1 (en) | Method of enhancing effect of a neurotrophin with analogues of p75NTR367-379. | |
WO2020109526A8 (en) | Oxyntomodulin peptide analog formulations | |
US10981958B2 (en) | Peptide modulator of purinergic receptors | |
Dolbeare et al. | iso-Lactam and reduced amide analogues of the peptidomimetic dopamine receptor modulator 3 (R)-[(2 (S)-Pyrrolidinylcarbonyl) amino]-2-oxo-1-pyrrolidineacetamide | |
Gottschlich et al. | EMD 61 753 as a favourable representative of structurally novel arylacetamido-type K opiate receptor agonists | |
Wei et al. | Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives | |
WO2004083867A3 (en) | Modulators of g protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |